1 Market Overview

1.1 Product Overview and Scope of Microbiome Drugs

1.2 Classification of Microbiome Drugs by Type

1.2.1 Overview: Global Microbiome Drugs Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Microbiome Drugs Revenue Market Share by Type in 2021

1.2.3 Oral Dosage Form

1.2.4 Enteric Capsules

1.3 Global Microbiome Drugs Market by Symptom

1.3.1 Overview: Global Microbiome Drugs Market Size by Symptom: 2017 Versus 2021 Versus 2028

1.3.2 Gastrointestinal Disorders

1.3.3 Autoimmune Disorders

1.3.4 Diabetes

1.3.5 Cancer

1.3.6 Others

1.4 Global Microbiome Drugs Market Size & Forecast

1.5 Global Microbiome Drugs Market Size and Forecast by Region

1.5.1 Global Microbiome Drugs Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Microbiome Drugs Market Size by Region, (2017-2022)

1.5.3 North America Microbiome Drugs Market Size and Prospect (2017-2028)

1.5.4 Europe Microbiome Drugs Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Microbiome Drugs Market Size and Prospect (2017-2028)

1.5.6 South America Microbiome Drugs Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Microbiome Drugs Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Microbiome Drugs Market Drivers

1.6.2 Microbiome Drugs Market Restraints

1.6.3 Microbiome Drugs Trends Analysis

2 Company Profiles

2.1 Seres Therapeutics

2.1.1 Seres Therapeutics Details

2.1.2 Seres Therapeutics Major Business

2.1.3 Seres Therapeutics Microbiome Drugs Product and Solutions

2.1.4 Seres Therapeutics Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Seres Therapeutics Recent Developments and Future Plans

2.2 Assembly Biosciences

2.2.1 Assembly Biosciences Details

2.2.2 Assembly Biosciences Major Business

2.2.3 Assembly Biosciences Microbiome Drugs Product and Solutions

2.2.4 Assembly Biosciences Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Assembly Biosciences Recent Developments and Future Plans

2.3 Synthetic Biologics

2.3.1 Synthetic Biologics Details

2.3.2 Synthetic Biologics Major Business

2.3.3 Synthetic Biologics Microbiome Drugs Product and Solutions

2.3.4 Synthetic Biologics Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Synthetic Biologics Recent Developments and Future Plans

2.4 Interxon

2.4.1 Interxon Details

2.4.2 Interxon Major Business

2.4.3 Interxon Microbiome Drugs Product and Solutions

2.4.4 Interxon Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Interxon Recent Developments and Future Plans

2.5 PureTech

2.5.1 PureTech Details

2.5.2 PureTech Major Business

2.5.3 PureTech Microbiome Drugs Product and Solutions

2.5.4 PureTech Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 PureTech Recent Developments and Future Plans

2.6 Synlogic

2.6.1 Synlogic Details

2.6.2 Synlogic Major Business

2.6.3 Synlogic Microbiome Drugs Product and Solutions

2.6.4 Synlogic Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Synlogic Recent Developments and Future Plans

2.7 Enterome BioScience

2.7.1 Enterome BioScience Details

2.7.2 Enterome BioScience Major Business

2.7.3 Enterome BioScience Microbiome Drugs Product and Solutions

2.7.4 Enterome BioScience Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Enterome BioScience Recent Developments and Future Plans

2.8 4D Pharma

2.8.1 4D Pharma Details

2.8.2 4D Pharma Major Business

2.8.3 4D Pharma Microbiome Drugs Product and Solutions

2.8.4 4D Pharma Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 4D Pharma Recent Developments and Future Plans

2.9 Second Genome

2.9.1 Second Genome Details

2.9.2 Second Genome Major Business

2.9.3 Second Genome Microbiome Drugs Product and Solutions

2.9.4 Second Genome Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Second Genome Recent Developments and Future Plans

2.10 AOBiome

2.10.1 AOBiome Details

2.10.2 AOBiome Major Business

2.10.3 AOBiome Microbiome Drugs Product and Solutions

2.10.4 AOBiome Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 AOBiome Recent Developments and Future Plans

2.11 Rebiotix

2.11.1 Rebiotix Details

2.11.2 Rebiotix Major Business

2.11.3 Rebiotix Microbiome Drugs Product and Solutions

2.11.4 Rebiotix Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Rebiotix Recent Developments and Future Plans

2.12 Metabiomics

2.12.1 Metabiomics Details

2.12.2 Metabiomics Major Business

2.12.3 Metabiomics Microbiome Drugs Product and Solutions

2.12.4 Metabiomics Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Metabiomics Recent Developments and Future Plans

2.13 Ritter Pharmaceuticals

2.13.1 Ritter Pharmaceuticals Details

2.13.2 Ritter Pharmaceuticals Major Business

2.13.3 Ritter Pharmaceuticals Microbiome Drugs Product and Solutions

2.13.4 Ritter Pharmaceuticals Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Ritter Pharmaceuticals Recent Developments and Future Plans

2.14 Symberix

2.14.1 Symberix Details

2.14.2 Symberix Major Business

2.14.3 Symberix Microbiome Drugs Product and Solutions

2.14.4 Symberix Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Symberix Recent Developments and Future Plans

2.15 OpenBiome

2.15.1 OpenBiome Details

2.15.2 OpenBiome Major Business

2.15.3 OpenBiome Microbiome Drugs Product and Solutions

2.15.4 OpenBiome Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 OpenBiome Recent Developments and Future Plans

2.16 Azitra

2.16.1 Azitra Details

2.16.2 Azitra Major Business

2.16.3 Azitra Microbiome Drugs Product and Solutions

2.16.4 Azitra Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Azitra Recent Developments and Future Plans

2.17 Osel

2.17.1 Osel Details

2.17.2 Osel Major Business

2.17.3 Osel Microbiome Drugs Product and Solutions

2.17.4 Osel Microbiome Drugs Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Osel Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Microbiome Drugs Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Microbiome Drugs Players Market Share in 2021

3.2.2 Top 10 Microbiome Drugs Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Microbiome Drugs Players Head Office, Products and Services Provided

3.4 Microbiome Drugs Mergers & Acquisitions

3.5 Microbiome Drugs New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Microbiome Drugs Revenue and Market Share by Type (2017-2022)

4.2 Global Microbiome Drugs Market Forecast by Type (2023-2028)

5 Market Size Segment by Symptom

5.1 Global Microbiome Drugs Revenue Market Share by Symptom (2017-2022)

5.2 Global Microbiome Drugs Market Forecast by Symptom (2023-2028)

6 North America by Country, by Type, and by Symptom

6.1 North America Microbiome Drugs Revenue by Type (2017-2028)

6.2 North America Microbiome Drugs Revenue by Symptom (2017-2028)

6.3 North America Microbiome Drugs Market Size by Country

6.3.1 North America Microbiome Drugs Revenue by Country (2017-2028)

6.3.2 United States Microbiome Drugs Market Size and Forecast (2017-2028)

6.3.3 Canada Microbiome Drugs Market Size and Forecast (2017-2028)

6.3.4 Mexico Microbiome Drugs Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Symptom

7.1 Europe Microbiome Drugs Revenue by Type (2017-2028)

7.2 Europe Microbiome Drugs Revenue by Symptom (2017-2028)

7.3 Europe Microbiome Drugs Market Size by Country

7.3.1 Europe Microbiome Drugs Revenue by Country (2017-2028)

7.3.2 Germany Microbiome Drugs Market Size and Forecast (2017-2028)

7.3.3 France Microbiome Drugs Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Microbiome Drugs Market Size and Forecast (2017-2028)

7.3.5 Russia Microbiome Drugs Market Size and Forecast (2017-2028)

7.3.6 Italy Microbiome Drugs Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Symptom

8.1 Asia-Pacific Microbiome Drugs Revenue by Type (2017-2028)

8.2 Asia-Pacific Microbiome Drugs Revenue by Symptom (2017-2028)

8.3 Asia-Pacific Microbiome Drugs Market Size by Region

8.3.1 Asia-Pacific Microbiome Drugs Revenue by Region (2017-2028)

8.3.2 China Microbiome Drugs Market Size and Forecast (2017-2028)

8.3.3 Japan Microbiome Drugs Market Size and Forecast (2017-2028)

8.3.4 South Korea Microbiome Drugs Market Size and Forecast (2017-2028)

8.3.5 India Microbiome Drugs Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Microbiome Drugs Market Size and Forecast (2017-2028)

8.3.7 Australia Microbiome Drugs Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Symptom

9.1 South America Microbiome Drugs Revenue by Type (2017-2028)

9.2 South America Microbiome Drugs Revenue by Symptom (2017-2028)

9.3 South America Microbiome Drugs Market Size by Country

9.3.1 South America Microbiome Drugs Revenue by Country (2017-2028)

9.3.2 Brazil Microbiome Drugs Market Size and Forecast (2017-2028)

9.3.3 Argentina Microbiome Drugs Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Symptom

10.1 Middle East & Africa Microbiome Drugs Revenue by Type (2017-2028)

10.2 Middle East & Africa Microbiome Drugs Revenue by Symptom (2017-2028)

10.3 Middle East & Africa Microbiome Drugs Market Size by Country

10.3.1 Middle East & Africa Microbiome Drugs Revenue by Country (2017-2028)

10.3.2 Turkey Microbiome Drugs Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Microbiome Drugs Market Size and Forecast (2017-2028)

10.3.4 UAE Microbiome Drugs Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Microbiome Drugs Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Microbiome Drugs Revenue by Symptom, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Microbiome Drugs Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Microbiome Drugs Revenue (USD Million) by Region (2017-2022)

Table 5. Global Microbiome Drugs Revenue Market Share by Region (2023-2028)

Table 6. Seres Therapeutics Corporate Information, Head Office, and Major Competitors

Table 7. Seres Therapeutics Major Business

Table 8. Seres Therapeutics Microbiome Drugs Product and Solutions

Table 9. Seres Therapeutics Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Assembly Biosciences Corporate Information, Head Office, and Major Competitors

Table 11. Assembly Biosciences Major Business

Table 12. Assembly Biosciences Microbiome Drugs Product and Solutions

Table 13. Assembly Biosciences Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Synthetic Biologics Corporate Information, Head Office, and Major Competitors

Table 15. Synthetic Biologics Major Business

Table 16. Synthetic Biologics Microbiome Drugs Product and Solutions

Table 17. Synthetic Biologics Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Interxon Corporate Information, Head Office, and Major Competitors

Table 19. Interxon Major Business

Table 20. Interxon Microbiome Drugs Product and Solutions

Table 21. Interxon Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. PureTech Corporate Information, Head Office, and Major Competitors

Table 23. PureTech Major Business

Table 24. PureTech Microbiome Drugs Product and Solutions

Table 25. PureTech Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Synlogic Corporate Information, Head Office, and Major Competitors

Table 27. Synlogic Major Business

Table 28. Synlogic Microbiome Drugs Product and Solutions

Table 29. Synlogic Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Enterome BioScience Corporate Information, Head Office, and Major Competitors

Table 31. Enterome BioScience Major Business

Table 32. Enterome BioScience Microbiome Drugs Product and Solutions

Table 33. Enterome BioScience Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. 4D Pharma Corporate Information, Head Office, and Major Competitors

Table 35. 4D Pharma Major Business

Table 36. 4D Pharma Microbiome Drugs Product and Solutions

Table 37. 4D Pharma Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Second Genome Corporate Information, Head Office, and Major Competitors

Table 39. Second Genome Major Business

Table 40. Second Genome Microbiome Drugs Product and Solutions

Table 41. Second Genome Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. AOBiome Corporate Information, Head Office, and Major Competitors

Table 43. AOBiome Major Business

Table 44. AOBiome Microbiome Drugs Product and Solutions

Table 45. AOBiome Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Rebiotix Corporate Information, Head Office, and Major Competitors

Table 47. Rebiotix Major Business

Table 48. Rebiotix Microbiome Drugs Product and Solutions

Table 49. Rebiotix Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Metabiomics Corporate Information, Head Office, and Major Competitors

Table 51. Metabiomics Major Business

Table 52. Metabiomics Microbiome Drugs Product and Solutions

Table 53. Metabiomics Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Ritter Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 55. Ritter Pharmaceuticals Major Business

Table 56. Ritter Pharmaceuticals Microbiome Drugs Product and Solutions

Table 57. Ritter Pharmaceuticals Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Symberix Corporate Information, Head Office, and Major Competitors

Table 59. Symberix Major Business

Table 60. Symberix Microbiome Drugs Product and Solutions

Table 61. Symberix Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. OpenBiome Corporate Information, Head Office, and Major Competitors

Table 63. OpenBiome Major Business

Table 64. OpenBiome Microbiome Drugs Product and Solutions

Table 65. OpenBiome Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Azitra Corporate Information, Head Office, and Major Competitors

Table 67. Azitra Major Business

Table 68. Azitra Microbiome Drugs Product and Solutions

Table 69. Azitra Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Osel Corporate Information, Head Office, and Major Competitors

Table 71. Osel Major Business

Table 72. Osel Microbiome Drugs Product and Solutions

Table 73. Osel Microbiome Drugs Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Global Microbiome Drugs Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 75. Global Microbiome Drugs Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 76. Breakdown of Microbiome Drugs by Company Type (Tier 1, Tier 2 and Tier 3)

Table 77. Microbiome Drugs Players Head Office, Products and Services Provided

Table 78. Microbiome Drugs Mergers & Acquisitions in the Past Five Years

Table 79. Microbiome Drugs New Entrants and Expansion Plans

Table 80. Global Microbiome Drugs Revenue (USD Million) by Type (2017-2022)

Table 81. Global Microbiome Drugs Revenue Share by Type (2017-2022)

Table 82. Global Microbiome Drugs Revenue Forecast by Type (2023-2028)

Table 83. Global Microbiome Drugs Revenue by Symptom (2017-2022)

Table 84. Global Microbiome Drugs Revenue Forecast by Symptom (2023-2028)

Table 85. North America Microbiome Drugs Revenue by Type (2017-2022) & (USD Million)

Table 86. North America Microbiome Drugs Revenue by Type (2023-2028) & (USD Million)

Table 87. North America Microbiome Drugs Revenue by Symptom (2017-2022) & (USD Million)

Table 88. North America Microbiome Drugs Revenue by Symptom (2023-2028) & (USD Million)

Table 89. North America Microbiome Drugs Revenue by Country (2017-2022) & (USD Million)

Table 90. North America Microbiome Drugs Revenue by Country (2023-2028) & (USD Million)

Table 91. Europe Microbiome Drugs Revenue by Type (2017-2022) & (USD Million)

Table 92. Europe Microbiome Drugs Revenue by Type (2023-2028) & (USD Million)

Table 93. Europe Microbiome Drugs Revenue by Symptom (2017-2022) & (USD Million)

Table 94. Europe Microbiome Drugs Revenue by Symptom (2023-2028) & (USD Million)

Table 95. Europe Microbiome Drugs Revenue by Country (2017-2022) & (USD Million)

Table 96. Europe Microbiome Drugs Revenue by Country (2023-2028) & (USD Million)

Table 97. Asia-Pacific Microbiome Drugs Revenue by Type (2017-2022) & (USD Million)

Table 98. Asia-Pacific Microbiome Drugs Revenue by Type (2023-2028) & (USD Million)

Table 99. Asia-Pacific Microbiome Drugs Revenue by Symptom (2017-2022) & (USD Million)

Table 100. Asia-Pacific Microbiome Drugs Revenue by Symptom (2023-2028) & (USD Million)

Table 101. Asia-Pacific Microbiome Drugs Revenue by Region (2017-2022) & (USD Million)

Table 102. Asia-Pacific Microbiome Drugs Revenue by Region (2023-2028) & (USD Million)

Table 103. South America Microbiome Drugs Revenue by Type (2017-2022) & (USD Million)

Table 104. South America Microbiome Drugs Revenue by Type (2023-2028) & (USD Million)

Table 105. South America Microbiome Drugs Revenue by Symptom (2017-2022) & (USD Million)

Table 106. South America Microbiome Drugs Revenue by Symptom (2023-2028) & (USD Million)

Table 107. South America Microbiome Drugs Revenue by Country (2017-2022) & (USD Million)

Table 108. South America Microbiome Drugs Revenue by Country (2023-2028) & (USD Million)

Table 109. Middle East & Africa Microbiome Drugs Revenue by Type (2017-2022) & (USD Million)

Table 110. Middle East & Africa Microbiome Drugs Revenue by Type (2023-2028) & (USD Million)

Table 111. Middle East & Africa Microbiome Drugs Revenue by Symptom (2017-2022) & (USD Million)

Table 112. Middle East & Africa Microbiome Drugs Revenue by Symptom (2023-2028) & (USD Million)

Table 113. Middle East & Africa Microbiome Drugs Revenue by Country (2017-2022) & (USD Million)

Table 114. Middle East & Africa Microbiome Drugs Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Microbiome Drugs Picture

Figure 2. Global Microbiome Drugs Revenue Market Share by Type in 2021

Figure 3. Oral Dosage Form

Figure 4. Enteric Capsules

Figure 5. Microbiome Drugs Revenue Market Share by Symptom in 2021

Figure 6. Gastrointestinal Disorders Picture

Figure 7. Autoimmune Disorders Picture

Figure 8. Diabetes Picture

Figure 9. Cancer Picture

Figure 10. Others Picture

Figure 11. Global Microbiome Drugs Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 12. Global Microbiome Drugs Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global Microbiome Drugs Revenue Market Share by Region (2017-2028)

Figure 14. Global Microbiome Drugs Revenue Market Share by Region in 2021

Figure 15. North America Microbiome Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Europe Microbiome Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Asia-Pacific Microbiome Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. South America Microbiome Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Middle East and Africa Microbiome Drugs Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Microbiome Drugs Market Drivers

Figure 21. Microbiome Drugs Market Restraints

Figure 22. Microbiome Drugs Market Trends

Figure 23. Seres Therapeutics Recent Developments and Future Plans

Figure 24. Assembly Biosciences Recent Developments and Future Plans

Figure 25. Synthetic Biologics Recent Developments and Future Plans

Figure 26. Interxon Recent Developments and Future Plans

Figure 27. PureTech Recent Developments and Future Plans

Figure 28. Synlogic Recent Developments and Future Plans

Figure 29. Enterome BioScience Recent Developments and Future Plans

Figure 30. 4D Pharma Recent Developments and Future Plans

Figure 31. Second Genome Recent Developments and Future Plans

Figure 32. AOBiome Recent Developments and Future Plans

Figure 33. Rebiotix Recent Developments and Future Plans

Figure 34. Metabiomics Recent Developments and Future Plans

Figure 35. Ritter Pharmaceuticals Recent Developments and Future Plans

Figure 36. Symberix Recent Developments and Future Plans

Figure 37. OpenBiome Recent Developments and Future Plans

Figure 38. Azitra Recent Developments and Future Plans

Figure 39. Osel Recent Developments and Future Plans

Figure 40. Global Microbiome Drugs Revenue Share by Players in 2021

Figure 41. Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 42. Global Top 3 Players Microbiome Drugs Revenue Market Share in 2021

Figure 43. Global Top 10 Players Microbiome Drugs Revenue Market Share in 2021

Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 45. Global Microbiome Drugs Revenue Share by Type in 2021

Figure 46. Global Microbiome Drugs Market Share Forecast by Type (2023-2028)

Figure 47. Global Microbiome Drugs Revenue Share by Symptom in 2021

Figure 48. Global Microbiome Drugs Market Share Forecast by Symptom (2023-2028)

Figure 49. North America Microbiome Drugs Sales Market Share by Type (2017-2028)

Figure 50. North America Microbiome Drugs Sales Market Share by Symptom (2017-2028)

Figure 51. North America Microbiome Drugs Revenue Market Share by Country (2017-2028)

Figure 52. United States Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Canada Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Mexico Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Europe Microbiome Drugs Sales Market Share by Type (2017-2028)

Figure 56. Europe Microbiome Drugs Sales Market Share by Symptom (2017-2028)

Figure 57. Europe Microbiome Drugs Revenue Market Share by Country (2017-2028)

Figure 58. Germany Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. France Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. United Kingdom Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Russia Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Italy Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Asia-Pacific Microbiome Drugs Sales Market Share by Type (2017-2028)

Figure 64. Asia-Pacific Microbiome Drugs Sales Market Share by Symptom (2017-2028)

Figure 65. Asia-Pacific Microbiome Drugs Revenue Market Share by Region (2017-2028)

Figure 66. China Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Japan Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. South Korea Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. India Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Southeast Asia Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Australia Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. South America Microbiome Drugs Sales Market Share by Type (2017-2028)

Figure 73. South America Microbiome Drugs Sales Market Share by Symptom (2017-2028)

Figure 74. South America Microbiome Drugs Revenue Market Share by Country (2017-2028)

Figure 75. Brazil Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Argentina Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Middle East and Africa Microbiome Drugs Sales Market Share by Type (2017-2028)

Figure 78. Middle East and Africa Microbiome Drugs Sales Market Share by Symptom (2017-2028)

Figure 79. Middle East and Africa Microbiome Drugs Revenue Market Share by Country (2017-2028)

Figure 80. Turkey Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Saudi Arabia Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. UAE Microbiome Drugs Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. Methodology

Figure 84. Research Process and Data Source